(S)-Ketamine in Refractory and Super-Refractory Status Epilepticus: A Retrospective Study

CNS Drugs

Volumn 30, Issue 9, 2016, Pages 869-876

  Höfler, Julia ^a,b   Rohracher, Alexandra ^a,b   Kalss, Gudrun ^a,b   Zimmermann, Georg ^a,b   Dobesberger, Judith ^a,b   Pilz, Georg ^a,b   Leitinger, Markus ^a,b   Kuchukhidze, Giorgi ^a,b,c   Butz, Kevin ^a,b   Taylor, Alexandra ^a,b   Novak, Helmut ^a,b   Trinka, Eugen ^a,b  

^a PARACELSUS MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY OF SALZBURG   (Austria)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

KETAMINE; PROPOFOL; AMINO ACID RECEPTOR BLOCKING AGENT; ANESTHETIC AGENT; ANTICONVULSIVE AGENT;

AGED; ANTICONVULSANT THERAPY; ARTICLE; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ELECTROENCEPHALOGRAM; EPILEPTIC STATE; FEMALE; HUMAN; LATENT PERIOD; MALE; MEDICAL RECORD REVIEW; NEUROLOGICAL INTENSIVE CARE UNIT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REFRACTORY STATUS EPILEPTICUS; RETROSPECTIVE STUDY; SUPER REFRACTORY STATUS EPILEPTICUS; TREATMENT DURATION; TREATMENT RESPONSE; DRUG RESISTANT EPILEPSY; ELECTROENCEPHALOGRAPHY; INTENSIVE CARE UNIT; MIDDLE AGED; TREATMENT OUTCOME;

AGED; ANESTHETICS; ANTICONVULSANTS; DRUG RESISTANT EPILEPSY; ELECTROENCEPHALOGRAPHY; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; HUMANS; INTENSIVE CARE UNITS; KETAMINE; MALE; MIDDLE AGED; PROPOFOL; RETROSPECTIVE STUDIES; STATUS EPILEPTICUS; TREATMENT OUTCOME;

EID: 84979996155     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-016-0371-2     Document Type: Article

References (45)

1. Shorvon S, Ferlisi M. The outcome of therapies in refractory and super-refractory convulsive status epilepticus and recommendations for therapy. Brain. 2012;135(Pt 8):2314–28.
2. Mayer SA, Claassen J, Lokin J, Mendelsohn F, Dennis LJ, Fitzsimmons BF. Refractory status epilepticus: frequency, risk factors, and impact on outcome. Arch Neurol. 2002;59:2015–210.
3. Kellinghaus C, Stögbauer F. Treatment of status epilepticus in a large community hospital. Epilepsy Behav. 2012;23:235–40.
4. Lowenstein DH, Bleck T, Macdonald RL. It’s time to revise the definition of Status epilepticus. Epilepsia. 1999;40(1):120–2.
5. Feng HJ, Mathews GC, Kao C, Macdonald RL. Alterations of GABA A-receptor function and allosteric modulation during development of status epilepticus. J Neurophysiol. 2008;99:1285–93.
6. Chen JW, Wasterlain CG. Status epilepticus: pathophysiology and management in adults. Lancet Neurol. 2006;5:246–56.
7. Jones S, Pahl C, Trinka E, Nashef L. A protocol for the inhospital emergency drug management of convulsive status epilepticus in adults. Pract Neurol. 2014;14:194–7.
8. Trinka E, Höfler J, Leitinger M, Brigo F. Pharmacotherapy for status epilepticus. Drugs. 2015;75:1499–521.
9. Borris DJ, Bertram EH, Kapur J. Ketamine controls prolonged status epilepticus. Epilepsy Res. 2000;42:117–22.
10. Mazarati AM, Wasterlain CG. N-methyl-d-asparate receptor antagonists abolish the maintenance phase of self-sustaining status epilepticus in rat. Neurosci Lett. 1999;23:187–90.
11. Oye I, Paulsen O, Maurset A. Effects of ketamine on sensory perception: evidence for a role of N-methyl-d-aspartate receptors. J Pharmacol Exp Ther. 1992;260(3):1209–13.
12. White PF, Schüttler J, Shafer A, Stanski DR, Horai Y, Trevor AJ. Comparative pharmacology of the ketamine isomers. Studies in volunteers. Br J Anaesth. 1985;57:197–203.
13. Engelhardt W, Stahl K, Marouche A, Hartung E. Recovery time after (S)-ketamine or ketamine racemate. Recovery time after short anesthesia in volunteers. Anaesthesist. 1998;47:184–92.
14. Beniczky S, Hirsch LJ, Kaplan PW, Pressler R, Bauer G, Aurlien H, Brøgger JC, Trinka E. Unified EEG terminology and criteria for nonconvulsive status epilepticus. Epilepsia. 2013;54(Suppl 6):28–9.
15. Trinka E, Leitinger M. Which EEG patterns in coma are nonconvulsive status epilepticus? Epilepsy Behav. 2015;49:203–22.
16. Trinka E, Cock H, Hesdorffer D, Rossetti AO, Scheffer IE, Shinnar S, Shorvon S, Lowenstein DH. A definition and classification of status epilepticus—report of the ILAE Task Force on Classification of Status Epilepticus. Epilepsia. 2015;56(10):1515–23.
17. Shorvon S, Baulac M, Cross H, Trinka E, Walker M. TaskForce on Status Epilepticus of the ILAE Commission for European Affairs. The drug treatment of status epilepticus in Europe: consensus document from a workshop at the first London Colloquium on Status Epilepticus. Epilepsia. 2008;49(7):1277–85.
18. Bauer G, Trinka E. Nonconvulsive status epilepticus and coma. Epilepsia. 2010;51(2):177–90.
19. Trinka E, Höfler J, Leitinger M, Rohracher A, Kalss G, Brigo F. Pharmacologic treatment of status epilepticus. Expert Opin Pharmacother. 2016;17(4):513–34.
20. Leitinger M, Kalss G, Rohracher A, Pilz G, Novak H, Höfler J, Deak I, Kuchukhidze G, Dobesberger J, Wakonig A, Trinka E. Predicting outcome of status epilepticus. Epilepsy Behav. 2015;49:126–30.
21. Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol. 1996;49:1373–9.
22. Pearson ES. The choice of statistical tests illustrated on the interpretation of data classed in a 2 × 2 table. Biometrika. 1947;34:139–67.
23. Brunner E, Munzel U. The nonparametric Behrens-Fisher problem: asymptotic theory and a small-sample approximation. Biom J. 2000;42:17–25.
24. Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat. 1979;6:65–70.
25. Agresti A. On logit confidence intervals for the odds ratio with small samples. Biometrics. 1999;55:597–602.
26. R Core Team. R A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria, 2014. http://www.R-project.org/.
27. Wu YW, Shek DW, Garcia PA, Zhao S, Johnston SC. Incidence and mortality of generalized convulsive status epilepticus in California. Neurology. 2002;58:1070–6.
28. Kowalski RG, Ziai WC, Rees RN, Werner JK Jr, Kim G, Goodwin H, Geocadin RG. Third-line antiepileptic therapy and outcome in status epilepticus: the impact of vasopressor use and prolonged mechanical ventilation. Crit Care Med. 2012;40(9):2677–84.
29. Sutter R, Marsch S, Fuhr P, Kaplan PW, Rüegg S. Anesthetic drugs in status epilepticus: risk or rescue? A 6-year cohort study. Neurology. 2014;82:656–64.
30. Marchi NA, Novy J, Faouzi M, Stähli C, Burnand B, Rossetti AO. Status epilepticus: impact of therapeutic coma on outcome. Crit Care Med. 2015;43(5):1003–9.
31. Gaspard N, Foreman B, Judd LM, Brenton JN, Nathan BR, McCoy BM, Al-Otaibi A, Kilbride R, Fernández IS, Mendoza L, Samuel S, Zakaria A, Kalamangalam GP, Legros B, Szaflarski JP, Loddenkemper T, Hahn CD, Goodkin HP, Claassen J, Hirsch LJ, Laroche SM. Intravenous ketamine for the treatment of refractory status epilepticus: a retrospective multicenter study. Epilepsia. 2013;54(8):1498–503.
32. Sabharwal V, Ramsay E, Martinez R, Shumate R, Khan F, Dave H, Iwuchukwu I, McGrade H. Propofol-ketamine combination therapy for effective control of super-refractory status epilepticus. Epilepsy Behav. 2015;52:264–6.
33. Synowiec AS, Singh DS, Yenugadhati V, Valeriano JP, Schramke CJ, Kelly KM. Ketamine use in the treatment of refractory status epilepticus. Epilepsy Res. 2013;105:183–8.
34. Basha MM, Alqallaf A, Shah AK. Drug-induced EEG pattern predicts effectiveness of ketamine in treating refractory status epilepticus. Epilepsia. 2015;56(4):44–8.
35. Koubeissi M, Alshekhlee A. In-hospital mortality of generalized convulsive status epilepticus: a large US sample. Neurology. 2007;69:886–93.
36. Walker MC, Howard RS, Smith SJ, Miller DH, Shorvon SD, Hirsch NP. Diagnosis and treatment of status epilepticus on a neurological intensive care unit. QJM. 1996;89:913–20.
37. Ubogu EE, Sagar SM, Lerner AJ, Maddux BN, Suarez JI, Werz MA. Ketamine for refractory status epilepticus: a case of possible ketamine-induced neurotoxicity. Epilepsy Behav. 2003;4:70–5.
38. Kofke WA, Bloom MJ, Van Cott A, Brenner RP. Electrographic tachyphylaxis to etomidate and ketamine used for refractory status epilepticus controlled with isoflurane. J Neurosurg Anesthesiol. 1997;9:269–72.
39. Robakis TK, Hirsch LJ. Literature review, case report, and expert discussion of prolonged refractory status epilepticus. Neurocrit Care. 2006;4:35–46.
40. Prüss H, Holtkamp M. Ketamine successfully terminates malignant status epilepticus. Epilepsy Res. 2008;82:219–22.
41. Hsieh CY, Sung PS, Tsai JJ, Huang CW. Terminating prolonged refractory status epilepticus using ketamine. Clin Neuropharmacol. 2010;33:165–7.
42. Yeh PS, Shen HN, Chen TY. Oral ketamine controlled refractory nonconvulsive status epilepticus in an elderly patient. Seizure. 2011;20:723–6.
43. Kramer AH. Early ketamine to treat refractory status epilepticus. Neurocrit Care. 2012;16:299–305.
44. Zeiler FA, Kaufmann AM, Gillman LM, West M, Silvaggio J. Ketamine for medically refractory status epilepticus after elective aneurysm clipping. Neurocrit Care. 2013;19:119–24.
45. Shrestha GS, Joshi P, Chhetri S, Karn R, Acharya SP. Intravenous ketamine for treatment of super-refractory convulsive status epilepticus with septic shock: a report of two cases. Indian J Crit Care Med. 2015;19:283–5.